X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17) 17
oncology (15) 15
humans (14) 14
lymphomas (13) 13
aged (11) 11
chemotherapy (11) 11
female (11) 11
male (11) 11
[sdv.can]life sciences [q-bio]/cancer (10) 10
lymphoma (10) 10
middle aged (10) 10
patients (10) 10
adult (9) 9
cancer (8) 8
hematology (8) 8
hodgkin lymphoma (8) 8
[ sdv.can ] life sciences [q-bio]/cancer (7) 7
life sciences (7) 7
aged, 80 and over (6) 6
hodgkin's disease (6) 6
disease-free survival (5) 5
hemic and lymphatic diseases (5) 5
open-label (5) 5
retrospective studies (5) 5
toxicity (5) 5
antibodies (4) 4
brentuximab vedotin (4) 4
cell death (4) 4
hematology, oncology and palliative medicine (4) 4
hodgkin disease - therapy (4) 4
immunotherapy (4) 4
medicine & public health (4) 4
nivolumab (4) 4
treatment outcome (4) 4
young adult (4) 4
adolescent (3) 3
antibodies, monoclonal - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
care and treatment (3) 3
cytotoxicity (3) 3
disease control (3) 3
etoposide (3) 3
lymphocytes b (3) 3
management (3) 3
medical research (3) 3
melanoma (3) 3
non-hodgkin-lymphoma (3) 3
positron-emission-tomography (3) 3
programmed cell death 1 receptor - antagonists & inhibitors (3) 3
programmed cell death 1 receptor - immunology (3) 3
radiation therapy (3) 3
radiotherapy (3) 3
risk factors (3) 3
studies (3) 3
survival rate (3) 3
tomography (3) 3
tumors (3) 3
[sdv]life sciences [q-bio] (2) 2
analysis (2) 2
anti-programmed death 1 (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
apoptosis (2) 2
b-cell lymphoma (2) 2
bendamustine (2) 2
cardiology (2) 2
cell survival (2) 2
cheson (2) 2
clinical trials (2) 2
criteria (2) 2
cytarabine - administration & dosage (2) 2
cytarabine - adverse effects (2) 2
diseases (2) 2
drug therapy (2) 2
emergent adverse event (2) 2
eosinophilia (2) 2
etoposide - administration & dosage (2) 2
etoposide - adverse effects (2) 2
experience (2) 2
expression (2) 2
hodgkin disease - mortality (2) 2
imaging / radiology (2) 2
immune checkpoint (2) 2
immune system diseases (2) 2
immune-related adverse event (2) 2
ipilimumab (2) 2
kinetics (2) 2
ligands (2) 2
medical prognosis (2) 2
medical treatment (2) 2
medicine, experimental (2) 2
nuclear medicine (2) 2
orthopedics (2) 2
patient (2) 2
pd-1 blockade (2) 2
pd-l1 protein (2) 2
pembrolizumab (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1496 - 1496
Patient's selection in early phase clinical trials is guided by stringent clinical criteria and can be supported or improved by precise tumor characterization... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 2952 - 2952
Abstract Background: Recent results of immune checkpoint blockade trials have provided a proof of concept for immunotherapy in classical Hodgkin lymphoma (cHL)... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2001 - 2001
Abstract Background: Treatments of patients with relapsed or refractory multiple myeloma (r/r MM) remains a challenge and there is no molecular-informed... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4226 - 4226
Abstract Background: The treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) remains challenging. The use of salvage chemotherapy... 
Journal Article
European journal of haematology, ISSN 0902-4441, 12/2019
High-dose cyclophosphamide to treat solid refractory tumors demonstrated meaningful activity, while data to treat lymphoma remains scarce. This study aims to... 
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 01/2018, Volume 59, Issue 1, pp. 15 - 24
The response evaluation criteria in patients with Hodgkin lymphoma (HL) were designed for the assessment of chemotherapy and targeted molecular agents. We... 
FDG-PET/CT | Immunomodulatory | Lugano | Cheson | Hodgkin lymphoma
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 85, p. 67
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2992 - 2992
Abstract INTRODUCTION The phase 1 selection for clinical trials of patients with relapsed or refractory Diffuse Large-B cell lymphoma (R/R DLBCL) with a... 
Journal Article
European Journal of Cancer, ISSN 0959-8049, 07/2017, Volume 80, p. 1
Case reports of three patients aged from 70 to 78 years who were presented with immune-related bone marrow failure as an immunre-related aplastic anaemia... 
Adenocarcinoma | Hematology | Anemia | Blood tests | Case reports | Cytotoxicity | Thorax | Radiation therapy | Patients | Case studies | Lungs | Pancytopenia | Bone marrow | Immune system
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 22, pp. 2473 - 2481
Journal Article
European Journal of Cancer, ISSN 0959-8049, 03/2018, Volume 91, p. 136
Background: We aimed to define the depth and time of maximal anti-tumour response to programmed death-1 blockade antibodies (anti-PD1) in heavily pre-treated... 
Immune checkpoint | Medical treatment | Tomography | Lymphomas | Kinetics
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.